|drug1363||Group B (Placebo) Wiki||1.00|
|drug1358||Group A (AG0302-COVID19) Wiki||1.00|
|drug1359||Group A (Placebo) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
Description: Frequency and severity of each adverse event solicited local and systemic AEs from the first vaccination to 4 weeks after the second vaccinationMeasure: Incidence of Treatment-Emergent Adverse Events Time: Group A: 6 weeks Group B: 8 weeks
Description: Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibodyMeasure: Immunogenicity Time: Group A: Week 7 Group B: Week 9
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports